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INTRODuCTION
The treatment modalities and treatment 
results of early and advanced rectal cancer have 
significantly improved during the last two decades. 
Although surgery is the leading treatment modality 
for rectal cancer, the multidisciplinary management 
has shown to achieve best clinical results (44).
The introduction of total mesorectal 
excision (TME) is the most significant treatment 
improvement reducing the local recurrence (LR) 
rate to less than 10%, compared with 30% with 
older surgical techniques. The advances in both 
pathology and imaging additionally have improved 
the multidisciplinary management (44).
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The role of adjuvant radiotherapy (RT) for rectal 
cancer has been well established in multiple clinical 
trials (39,48). RT either alone or with chemotherapy 
is applied mostly for locally advanced disease, before 
or after surgery. Chemoradiation (CRT) is often 
used before surgery. Preoperative RT (at biologically 
effective doses ≥30 Gy) and postoperative RT reduce 
the risk of LR from rectal cancer by 50% (8).
In this article, we review findings from the 
multiple clinical trials addressing the application 
of RT in the multimodality management of rectal 
cancer and defining the current standard of RT 
and the unanswered questions in the treatment of 
patients with rectal cancer.
Trial evidence
Preoperative RT or surgery alone
When preoperative RT for resectable tumours 
is applied before surgery, improved local control (LC) 
over surgery alone is reported.
Swedish Rectal Cancer Trial (12,30) included 
1,168 patients with resectable rectal cancer 
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randomized to preoperative RT (5/25 Gy) and surgery 
versus surgery alone (non-TME surgery). The RT 
arm showed improved 5-year LR (11% versus 27%) 
and 5-year overall survival (oS) (58% versus 48%). 
The continuous follow-up showed thirteen-year oS 
38% for RT arm versus 30% with increased risk of 
postoperative hospitalization for gastrointestinal 
(GI) complication in the RT arm.
Dutch Colorectal Cancer Group (TME trial) 
(24,31) randomized 1,861 patients with resectable 
rectal cancer to preoperative RT (25 Gy in 5 
fractions) and surgery versus surgery alone (TME 
surgery). An improved 2-year LR (2% versus 8%), 
5-year LR (6% versus 12%) and 10-year LR (5% versus 
10%) with no difference in survival were reported 
in the RT arm. The gastrtointestinal toxicity at 5 
years was higher in RT arm. A 12-year-long follow-
up showed significantly improved 10-year survival 
in stage III patients with negative circumferential 
resection margins (CRM) when RT was applied 
before surgery to surgery alone (50% versus 40%; 
p=0,032) (45). The rate of secondary malignancy 
and the non-cancer-related dead was higher in RT 
arm (14% versus 9%).
After standardization of TME, no oS benefit 
in a preoperative randomized trial was found. 
However, the long follow-up demonstrated a 
survival benefit (45).
Preoperative chemoradiation or preoperative RT 
Preoperative RT aims to lower the LR, to 
improve the resectability with higher R0-resections 
when mesorectal fascia (MRF) involvement is 
suspected or T4 disease, and to increase the sphincter 
preservation. There are two different preoperative 
RT approaches.
The preoperative RT is either short-course 
RT, or long-course CRT. The short-course RT 
(5x5 Gy) followed by surgery one week later on is 
applied mostly in Scandinavia. The long-course RT 
includes 50,4 Gy in 28 fractions with concurrent 
chemotherapy and the surgery is performed 4-8 
weeks later on. When needed boost to a 55,4 Gy total 
dose could be applied. Intraoperative radiotherapy 
(IoRT) or brachytherapy could be used for boost but 
they are not applied routinely. The short-course RT 
disadvantages are the lack of sphincter preservation, 
the inability to safely combine it with adequate doses 
of chemotherapy, and the toxicity (42). The ongoing 
Stockholm III trial tests if delayed surgery from 4 to 8 
weeks after short-course RT could obtain downsizing 
with sphincter preservation (32). Its advantage is the 
short treatment time interval compared to CRT. The 
advantage of CRT is the higher rate of downsizing 
and downstaging with higher pathological complete 
response (pCR), improved CRM, sphincter 
preservation, and lower rate of LR. 
French FFCD 9203 (15) study included 733 
resectable rectal cancer patients with T3/4N0 
randomized to preoperative RT (1,8/45 Gy) versus 
preoperative CRT (bolus 5FU-LV). Four more cycles 
of 5-FU-LV were added. pCR (4% versus 11%) and LC 
(83% versus 92%) were improved with preoperative 
RT, but 3-4 grade toxicity was higher (3% versus 15%). 
There was no difference in oS (67%) and sphincter 
preservation (52%).
EoRTC 22921 (4) trial included 1,011 patients 
with resectable rectal cancer randomized to 
preoperative RT, preoperative CRT, preoperative RT 
and postoperative chemotherapy, or preoperative 
chemotherapy and postoperative CRT. RT of 45 
Gy and 5-FU-LV chemotherapy were used (2 plus 
4 cycles). No significant difference in 5-year oS 
between preoperative and postoperative chemo-
groups (64,8% versus 65,8%). For CRT groups, 5-year 
LR rate was improved (by 8,7%; 9,6% and 7,6%) 
compared to RT alone group (17,1%)(p=0,002). CRT 
increased the pCR rate (5% versus 14%). Disease free 
survival (DFS) and oS differed significantly between 
the T0-2 and the T3-4 patients (p=0,009): only the 
T0-2 patients seemed to benefit from adjuvant 
chemotherapy (p=0,011) (7).
Polish Colorectal Study Group (5) investigated 
312 patients with T3/4 resectable rectal cancer 
randomized to preoperative short-course RT (5/25 
Gy) and surgery versus preoperative CRT (50,4 
Gy with bolus 5-FU-LV) and surgery. In the CRT 
group, higher acute toxicity (18,2% versus 3,2%) 
but no increased oS, LC, or late toxicity were 
observed compared to short-course RT alone. only 
downstaging was higher with CRT.
Trans-Tasman Radiation oncology Group 
trial 01.04 (28) included 326 patients with T3 rectal 
cancer randomized to preoperative short-course RT 
(5/25 Gy) and surgery versus preoperative CRT (50,4 
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Gy with 5-FU continuous infusion) and surgery. 
Three-year LR rates between short-course RT and 
CRT were not statistically significantly different. No 
differences in rates of distant recurrence, DFS, oS, or 
late toxicity were detected. 
Preoperative CRT according to these studies 
increases the pCR (by 5% versus 15%) and LC (by 
80-85% versus 90%), but does not lead to sphincter 
preservation (50%) or increased oS (65%) compared 
with preoperative RT alone.
Short-course RT appears to give the reasonable 
LC and the same oS like CRT and could be applied 
in resectable rectal cancer patients where downsizing 
is not necessary and MRF is not involved. However, 
short-course RT is much easier and more cost 
effective. Locally advanced tumours (i. e. involved 
MRF or cT4) require CRT.
Preoperative or postoperative CRT
German Rectal Cancer Study Group (38) 
investigated 823 rectal cancer patients with stage T3/4 
or positive lymph nodes randomized to preoperative 
versus postoperative CRT. All the patients received 
50,4 Gy with 5-FU and in the postoperative arm a 5,4 
Gy boost was applied. Preoperative CRT improved 
5-year LR rate (6% versus 13%), increased sphincter 
preservation surgery rate (39% versus 19%) and 
decreased the early and late toxicity. No difference 
in survival was revealed.
MRC CR07/NCIC-CTG C016 (40) was a Phase 
III trial and included 1,350 patients with resectable 
rectal cancer randomized to preoperative short-
course RT (5 /25Gy) and surgery compared to 
surgery and selective postoperative CRT (45 Gy and 
5-FU) given only to patients with involved CRM. 
Lower LR rate was observed in the preoperative 
RT arm versus the selective postoperative CRT 
arm (4,4% versus 10,6%) with no improved oS. 
Preoperative CRT achieved better LC with less 
morbidity compared to postoperative CRT.
CRT with different regimens
CRT should be given with fluoropyrimidine 
chemotherapy. The standard preoperative CRT 
includes 5-FU administered as continuous 
infusion (better than bolus) or oral 5-FU prodrugs 
(capecitabine or UFT).
Since the NSABP R-04 trial and an AIo trial 
have proved that 5-FU and capecitabine are equivalent 
(22,37), capecitabine becomes the preferred drug. It 
is applied in a dose of 825 mg/m2 twice a day.
The combination of 5-FU and oxaliplatin 
or irinotecan plus irradiation were evaluated in 
II and III phase trials for response rate and acute 
toxicity. Despite the expectation in the STAR-01, 
ACCoRD 12/0405-Prodige 2, and NSABP R-04 
trials (2,16,37) no increase in the complete pCR was 
observed when 5-FU/oxaliplatin or capecitabine/
oxaliplatin regimens were used compared to 5-FU 
alone. one trial only, CAo/ARo/AIo-04, showed 
a significant increase of pCR by 4,5% (34) Because 
of the increased acute toxicity and not improved 
pCR, oxaliplatin is not included in the standard 
preoperative CRT regimens. Survival and LC rates 
in the above mentioned and the ongoing PETACC 6 
trials are expected to evaluate the benefit of combined 
regimens.
Targeted agents such as bevacizumab and 
cetuximab were investigated within preoperative 
CRT regimens, too (9,46). The results are interesting 
but conflicting and their use out of clinical trial is 
not recommended.
Organ preservation and ‘wait and watch’ 
approach in rectal cancer
Approximately 15-20% of the patients will 
achieve CR after preoperative CRT for advanced 
rectal cancer. Patients with ypT0 after CRT show 
only 5% positive nodes and a low recurrence rate 
(26). The need of radical surgery in case of complete 
clinical response (shown on biopsy) for distal rectal 
cancer was analyzed (19). The study included patients 
with cT1-3 disease and ‘watch and wait’ policy was 
applied in case of clinical CR to CRT. Surgery was 
performed after a recurrence occurred. A 5-year 
oS and DFS were 96% and 72%, respectively, but no 
reproducibility of the results was achieved by other 
authors. The pCR after CRT for cT3 stage could be 
evaluated only by radical surgery since no imaging 
modality is sufficient (11,14,17). Two other trials 
interested in optimal timing of surgery are recruiting 
patients in the United Kingdom now (1,41).
The use of local excision after preoperative 
CRT is rising. The following LR rates were achieved, 
respectively: 2% in ypT1 and 6%-20% in ypT2 (3). 
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In non-responders, LR rate of 43% in ypT3 tumours 
was observed. In another study (26) including 320 
patients with T2-4N0-1 rectal cancer, 14 patients with 
ypT0 disease received local excision only. In a mean 
of 48 months following-up period, no LR or distant 
failure were observed. The ACoSoG Z6031 trial 
investigated full-thickness local excision in patients 
with uT2N0 disease after an oxaliplatin-capecitabine 
CRT (13). Patients with stage ypT0-2 disease and 
negative margins after local excision were observed 
only. The patients with stage ypT3 and/or positive 
margins received radical surgery. A pCR rate of 
43% was observed in a total of 77 patients. LR and 
survival data were expected. A similar French trial 
GRECCAR 2 is ongoing. Although preliminary 
results suggest that local excision may be an option 
in ypT0 patients, long-term follow-up is required and 
more accurate non-invasive diagnostic predicting 
ypT0 disease is necessary (6). 
IORT 
IoRT is delivered during surgery. There are 
two IoRT modalities - intraoperative electron 
beam radiotherapy (IoERT) and high-dose rate 
brachytherapy. IoRT is usually combined with 
external beam radiotherapy (EBRT) with or without 
chemotherapy and surgical resection. National 
Comprehensive Cancer Network (NCCN) USA 
guidelines recommend the use of IoRT in case of 
very close or positive margins after resection as an 
additional boost, especially for patients with T4 or 
recurrent cancers. 
IORT in locally advanced rectal cancer
For patients with rectal cancer, IoRT improves 
the LC. Adjuvant IoRT could improve the response 
rates with no serious toxicities and the survival as well 
in locally advanced colorectal cancer (21,33). Thus, 
the positive impact of IoRT on LC of CRC cancer 
justifies the inclusion of this therapeutic modality.
IORT in locally recurrent rectal cancer
Despite the significant advances in the treatment 
of primary rectal cancer with the introduction of 
TME and preoperative CRT, the observed LR rate is 
around 5-15% (31,38). The mean survival following 
locoregional relapse after resection is 11 to 15 months 
(25,27), and 5-year oS is 5% (18,47). In 50% of the 
patients, no metastatic disease is present (29) but the 
morbidity remains high (20) and local treatment 
options should be offered including surgery. In 
most cases, the radical surgery is not possible due to 
altered anatomy and tumour growth (10). Because 
of previous EBRT in most of the patients there is a 
limited room for external beam reirradiation in 
terms of normal tissue tolerance. In these cases, 
IoRT application in addition to surgery is reasonable. 
IoRT advantages are that the radiation field could be 
defined very simply with removing the healthy tissue 
out of the treatment field (35).
In the German study, 97 patients with locally 
recurrent rectal cancer received IoERT (36). In the 
patients without any previous irradiation, 10-15 Gy 
IoERT was combined with EBRT. Patients who had 
been previously irradiated received 15-20 Gy IoERT 
alone. The mean survival was 39 months with a 
5-year oS rate of 30% and a 5-year LC rate of 41%. 
In patients with R0 resection, 5-year oS and LC rates 
were 63% and 68%, respectively. In patients with R1 
and R2 resection, the observed 5-year oS and LC 
rates were worst (11% and 19%, respectively).
In a large trial (20) including 607 patients, 
5-year oS of 30% and LC rate of 72% were reported. 
A similar 5-year oS of 31,5% was achieved in another 
study (10) while 5-year LC rate was 50%.
Brachytherapy boost
High dose rate (HDR) brachytherapy is used 
in case of advanced tumours (>3 cm T1/T2/T3a 
N1 M0). After initial downstaging with EBRT and 
concurrent chemotherapy, HDR brachytherapy 
could be applied when there is a visible or palpable 
persistent tumour. By this way, the deeper residual 
tumour receives a higher radiation dose. Transanal 
endoscopic microsurgery (TEMS) is an option when 
minimal residual disease <2 cm is present (43). A 
phase 3 randomized Danish trial compared HDR 
rectal boost following CRT with CRT alone. HDR 
boost improved the pCR rates and R0 resection ones 
in T3 rectal tumours (23).
CONCLuSION
Although the surgery is the mainstay in 
the treatment of rectal cancer, its multimodality 
management is recommended based on the evidence 
available. In this rapidly developing field, RT applied 
either as neoadjuvant or adjuvant treatment plays an 
important role in the management of local advanced 
disease or in case of limited surgical intervention.
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